Fundraising Fox

Thunder Biotech

Alpine, US · Founded 2016 · Delaware corporation · 14 employees on LinkedIn · 1 known investors

Thunder Biotech is a cancer immunotherapy company developing MOTO-CAR treatments, which genetically engineer a patient's own macrophages into chimeric antigen receptor cells that target biomarkers on tumor cells to attack solid tumors. It focuses on immunotherapy for cancer patients with solid tumors.

BiotechHealthtechLongevityMedical Devices

Founders & leadership

Thunder Biotech was founded in 2016 by D. Tod Schulthess and Kim O'Neill.

DT
D. Tod SchulthessCo-founder
KO
Kim O'NeillFounder & Chief Scientific Officer
KL
Kim L. O'NeillNamed on SEC filing

Board

DB
D. Brent IsraelsenBoard director

Investors · 1

STARTUP IGNITION VENTURESProvo · $100K – $1M

Reported raises · per SEC filings

Form D private placements

$24.5M disclosed across 7 rounds · 2017–2024

▶$100KraisedFeb 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kent MisenerDirector
  • Kim O'NeillExecutive Officer, Director
  • James BurgessExecutive Officer
  • Barry MowerDirector
  • Jeff HoneExecutive Officer, Director
  • Steven TannerDirector
  • Scott PetersonDirector
  • Jeffrey NelsonDirector
Offering amount
$2.5M
Amount sold
$100K
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey R. NelsonDirector
  • Steven A. TannerDirector
  • Kim L. O'NeillExecutive Officer, Director
  • Robert P.K. MooneyExecutive Officer, Director
  • J. Anthony AntonelliDirector
  • Barry D. MowerDirector
  • Morris LintonExecutive Officer
  • James BurgessExecutive Officer
  • Kent A. MisenerDirector
Offering amount
$20M
Amount sold
$1M
Minimum investment
$250K
Sales commissions
$800K
Proceeds to insiders
$1.5M
Placement agents
Mann Mann Jensen Partners LP
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedOct 2022 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • D. Brent IsraelsenExecutive Officer, Director
  • Kim L. O'NeillExecutive Officer, Director
  • Kent A. MisenerDirector
  • Morris LintonExecutive Officer, Director
  • Steven A. TannerDirector
  • James BurgessExecutive Officer
Offering amount
$15M
Amount sold
$4M
Proceeds to insiders
$632.8K
First sale
Nov 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedAug 2022 · 52 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James BurgessExecutive Officer
  • Kent A. MisenerDirector
  • Steven A. TannerDirector
  • Morris LintonExecutive Officer, Director
  • Kim L. O'NeillExecutive Officer, Director
  • D. Brent IsraelsenExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
Proceeds to insiders
$1.7M
First sale
Sep 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.3MraisedAug 2022 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James BurgessExecutive Officer
  • Kim L. O'NeillExecutive Officer, Director
  • Morris LintonExecutive Officer, Director
  • Steven A. TannerDirector
  • D. Brent IsraelsenExecutive Officer, Director
  • Kent A. MisenerDirector
Offering amount
$10M
Amount sold
$8.3M
Proceeds to insiders
$1.4M
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$325KraisedNov 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • D. Todd SchulthessExecutive Officer, Director, Promoter
  • Kim L. O'NeillDirector
  • D. Brent IsraelsenExecutive Officer, Director
Offering amount
$18M
Amount sold
$325K
First sale
Oct 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$770KraisedMay 2017 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • D. Tod SchulthessExecutive Officer, Director, Promoter
  • D. Brent IsraelsenDirector
  • Kim L. O'NeillExecutive Officer, Director
Offering amount
$2M
Amount sold
$770K
First sale
Jan 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Thunder Biotech do?
Thunder Biotech is a cancer immunotherapy company developing MOTO-CAR treatments, which genetically engineer a patient's own macrophages into chimeric antigen receptor cells that target biomarkers on tumor cells to attack solid tumors. It focuses on immunotherapy for cancer patients with solid tumors.
Who founded Thunder Biotech?
Thunder Biotech was founded by D. Tod Schulthess, Kim O'Neill in 2016.
Who are Thunder Biotech's investors?
Thunder Biotech's investors include STARTUP IGNITION VENTURES.
How much funding has Thunder Biotech raised?
Thunder Biotech has disclosed $24.5M raised across 7 rounds.
Where is Thunder Biotech headquartered?
Thunder Biotech is headquartered in Alpine, US.